We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
-21.84%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$218M
AUM Growth
-$87.2M
(-29%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-4.72%
Top 10 Holdings %
Top 10 Hldgs %
82.07%
Holding
26
New
5
Increased
5
Reduced
6
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$12.3M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$9.96M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.79M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$5.14M |
| 5 |
SI-BONE Inc
SIBN
|
+$3.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$16.7M |
| 2 |
Omeros
OMER
|
+$8.69M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$8.21M |
| 4 |
Arbutus Biopharma
ABUS
|
+$5.39M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$5.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $31.7M | 14.53% |
855,900
+4,700
| +0.6% | +$169K |
|
2
Insmed
INSM
$21.4B
| $25.9M | 11.91% |
1,977,236
+176,649
| +10% | +$2.82M |
|
|
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $23.8M | 10.91% |
486,624
-24,620
| -5% | -$1.36M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $20.7M | 9.5% |
2,631,258
+607,889
| +30% | +$5.79M |
|
|
IMMU
5
DELISTED
Immunomedics Inc
IMMU
| $17.2M | 7.9% |
1,205,363
-26,180
| -2% | -$520K |
|
6
Ascendis Pharma A/S
ASND
$16B
| $15.4M | 7.06% |
245,424
| – | – |
|
7
Replimune Group
REPL
$941M
| $12.3M | 5.64% |
1,229,656
| – | – |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.81B
| $10.8M | 4.94% |
400,000
-296,903
| -43% | -$8.21M |
|
|
OPTN
9
DELISTED
OptiNose
OPTN
| $10.6M | 4.86% |
113,903
+16,667
| +17% | +$2.38M |
|
|
ORTX
10
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $10.5M | 4.83% |
+66,836
| New | +$9.96M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
| $9.45M | 4.34% |
+261,823
| New | +$12.3M |
|
|
12
Arbutus Biopharma
ABUS
$857M
| $6.06M | 2.78% |
1,582,275
-1,094,550
| -41% | -$5.39M |
|
|
EIDX
13
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $5.94M | 2.73% |
431,781
-93,219
| -18% | -$1.18M |
|
14
Aclaris Therapeutics
ACRS
$726M
| $5.53M | 2.54% |
748,132
+218,581
| +41% | +$2.25M |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.88M | 2.24% |
+250,000
| New | +$5.14M |
|
|
16
SI-BONE Inc
SIBN
$788M
| $4.29M | 1.97% |
+205,621
| New | +$3.89M |
|
17
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $1.8M | 0.82% |
63,922
-30,555
| -32% | -$638K |
|
18
Cytokinetics
CYTK
$10.5B
| $1.11M | 0.51% |
+175,148
| New | +$1.28M |
|
19
Crinetics Pharmaceuticals
CRNX
$8.84B
| – | – |
-49,600
| Closed | -$1.42M |
|
|
20
Omeros
OMER
$857M
| – | – |
-356,000
| Closed | -$8.69M |
|
21
uniQure
QURE
$3.03B
| – | – |
-10,650
| Closed | -$388K |
|
22
Arcus Biosciences
RCUS
$3.55B
| – | – |
-295,000
| Closed | -$4.11M |
|
|
VRNA
23
DELISTED
Verona Pharma
VRNA
| – | – |
-8,302
| Closed | -$104K |
|
|
24
Xenon Pharmaceuticals
XENE
$6.06B
| – | – |
-385,714
| Closed | -$5.09M |
|
|
GRTS
25
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-175,000
| Closed | -$2.49M |
|
Similar funds
BCM
AG
FL
PVM
MFA
TCM
WW
CB
Foresite Capital Management IV's Q4 2018 Portfolio in Review
As of Q4 2018, Foresite Capital Management IV held 26 positions worth $218M, down 29% from $305M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Foresite Capital Management IV withdrew a net $10.3M in Q4 2018, closing 8 positions and reducing 6 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $16.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier.
Against the trend, Foresite Capital Management IV opened a new position in Aerie Pharmaceuticals worth $9.45M.
- Foresite Capital Management IV's largest Q4 2018 buy was Aerie Pharmaceuticals: 261,823 shares worth $9.45M.
- Foresite Capital Management IV added most to Cymabay Therapeutics in Q4 2018, an estimated $5.79M increase.
- Foresite Capital Management IV's biggest Q4 2018 reduction was Rhythm Pharmaceuticals, cutting an estimated $8.21M.
- Foresite Capital Management IV fully exited Alder Biopharmaceuticals in Q4 2018, selling an estimated $16.7M.
- Foresite Capital Management IV's ten largest holdings make up 82% of its $218M portfolio in Q4 2018.
- Foresite Capital Management IV opened 5 new positions and closed 8 in Q4 2018.
- Foresite Capital Management IV's portfolio value fell 29% quarter-over-quarter to $218M.
Based on Foresite Capital Management IV's 13F filing for Q4 2018, filed 13 Feb 2019.